BioSpace News Archive

Medtronic plc, a global leader in healthcare technology, announces that it has entered into a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals.

SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi SAR443579 induced clinical benefit in patients with R/R AML with 5 complete remissions (4 CR / 1 CRi) achieved at 1 mg/kg, and was well tolerated up to doses of 6 mg/kg SAR443579 demonstrated durable responses with two responders remaining in remissi

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced data from a real-world case series evaluating treatment of three complete concentric collapse patients with the Genio® hypoglossal nerve stimulation system.

Ryvu Therapeutics presents clinical and preclinical data on RVU120, a selective CDK8/19 inhibitor, at the 65th American Society of Hematology Annual Meeting & Exposition, which is held on December 9-12, 2023, in San Diego, California.

Faron Pharmaceuticals Ltd. announced very positive Phase 1 data from the ongoing BEXMAB study in myeloid malignancies, being presented at the 65th American Society of Hematology Annual Meeting & Exposition taking place until tomorrow, December 12, 2023, in San Diego, California, and virtually.

Masimo announced the findings of a retrospective study published in the Journal of Anesthesia in which Dr. Yu Jeong Bang and colleagues at the Samsung Medical Center, Sungkyunkwan University School of Medicine, in Seoul, South Korea, investigated the association of Masimo ORi™ and the arterial partial pressure of oxygen in 554 patients who underwent non-cardiac thoracic surgery during one-lung ventilation, making this study the largest to date on ORi.

ANGLE plc is pleased to announce that Berenberg will act as the Company’s Nominated Adviser and Sole Broker with immediate effect.

ANGLE plc is delighted to announce the publication of breakthrough work by researchers at the University of New Mexico, US, into the role of CTC gene expression in the progression of melanoma brain metastasis.

Poolbeg Pharma announces key insights from its poster presentation at the prestigious, 65th American Society of Hematology Annual Meeting and Exposition, San Diego.

Milla Pharmaceuticals Inc., an A.forall company, announced that its partner, Acella Pharmaceuticals LLC, has just commercialized its Abbreviated New Drug Application approval from the U.S. Food and Drug Administration for a generic version of Mestinon® 60 mg/5mL.